持续提升制度包容性、适应性，资本市场精准赋能江苏高质量发展

Core Viewpoint - The article highlights the ongoing reforms in China's capital market, particularly in Jiangsu province, aimed at enhancing support for technology innovation enterprises and facilitating their access to financing through various initiatives and policies [1][2][8]. Group 1: Financing Reforms and Initiatives - The China Securities Regulatory Commission (CSRC) has introduced multiple measures such as the "16 Articles on Science and Technology Innovation" and the "8 Articles on the Science and Technology Innovation Board" to improve financing channels for innovative companies [1]. - Jiangsu's capital market has seen a significant increase in the number of listed companies, with 29 new domestic listings expected by 2025, accounting for 25% of the national total [1]. - A record was set for the speed of financing for small and medium-sized technology innovation enterprises, with a company completing the entire process from application to approval in just 34 trading days [2]. Group 2: Industry Development and Market Integration - Jiangsu's listed companies now cover a comprehensive "1650" industrial system, indicating a deep integration between the capital market and local industry [3]. - The semiconductor industry in Jiangsu is set to welcome two new listed companies by 2025, with one already marking a milestone as the first new stock on the Science and Technology Innovation Board this year [3]. - The biopharmaceutical sector is actively engaging with the capital market, with several companies expressing intentions to return to A-shares for development [3]. Group 3: New Industry Opportunities - The focus on future industries, such as artificial intelligence and commercial aerospace, is emphasized as part of Jiangsu's strategic development, with reforms extending support to these sectors [4][5]. - Several companies are planning to apply for the fifth set of standards on the Science and Technology Innovation Board, which caters to hard-tech enterprises that may not yet be profitable but represent future technological directions [5]. Group 4: Internationalization and Market Expansion - Jiangsu has seen an increase in companies successfully obtaining listings in Hong Kong, with the total number of A+H listed companies reaching 9, indicating a growing international presence [6]. - A biopharmaceutical company raised approximately HKD 9.89 billion in its IPO on the Hong Kong Stock Exchange, marking the largest financing scale in the Hong Kong medical sector since 2020 [6]. Group 5: Quality and Governance in Listings - The Jiangsu Securities Regulatory Bureau emphasizes the importance of balancing development and safety, focusing on high-quality listings through proactive regulatory support [7]. - Over 20 specialized policy seminars and case analysis meetings have been conducted to guide companies in establishing a correct understanding of the listing process and governance [7]. - The regulatory body aims to enhance the quality of listed companies by ensuring that capital flows towards enterprises that represent technological and industrial innovation [7]. Group 6: Future Outlook - The Jiangsu Securities Regulatory Bureau plans to enhance the inclusivity and adaptability of capital market systems to support technological self-reliance and cultivate new productive forces [8]. - The bureau will implement measures to ensure that supportive policies effectively reach enterprises, translating reform policies into development momentum [8].